Treatment recommendations for chronic myeloid leukemia

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 6, Issue 1, 2014, Pages

  Baccarani, Michele ^a   Castagnetti, Fausto ^b   Gugliotta, Gabriele ^b   Palandri, Francesca ^b   Rosti, Gianantonio ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EXPERIMENTAL THERAPY; HUMAN; LEUKEMIA REMISSION; OUTCOME ASSESSMENT; PATIENT SELECTION; QUALITY OF LIFE; REVIEW; TIME TO TREATMENT; TREATMENT PLANNING;

EID: 84894054358     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2014.005     Document Type: Review

References (68)

1. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108:1809-1820. http://dx.doi.org/10.1182/blood-2006-02-005686 PMid:16709930
2. Hehlmann R, Hochhaus A, Baccarani M, on behalf of the European LeukemiaNet. Chronic myeloid leukemia. Lancet 2007; 370:342-50. http://dx.doi.org/10.1016/S0140-6736(07)61165-9
3. Bjorkholm M, Ohm L, Eloranta S et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011;29:2514-2520. http://dx.doi.org/10.1200/JCO.2011.34.7146 PMid:21576640 PMCid:PMC3138632
4. Kantarjian H, O'Brien S, Jabbour E et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119:1981-1987 http://dx.doi.org/10.1182/blood-2011-08-358135 PMid:22228624 PMCid:PMC3311242
5. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27:6041-6051. http://dx.doi.org/10.1200/JCO.2009.25.0779 PMid:19884523
6. Baccarani M, Deininger M, Rosti A. et al. European LeukemiaNet 2013 recommendations for the management of chronic myeloid leukemia. Blood 2013;122:885-892. http://dx.doi.org/10.1182/blood-2013-05-501569 PMid:23803709
7. Pavlu J, Szydlo RM, Goldman JM, and Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011;117(3):755-763. http://dx.doi.org/10.1182/blood-2010-08-301341 PMid:20966165
8. Talpaz M, Hehlmann R, Quintas-Cardama A, et al. Re-emergence of interferon-? in the treatment of chronic myeloid leukemia. Leukemia 2013; 27:803-12. http://dx.doi.org/10.1038/leu.2012.313 PMid:23238589 PMCid:PMC3703612
9. O'Brien SG, Guilhot F, Larson R, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348:994-1004 http://dx.doi.org/10.1056/NEJMoa022457 PMid:12637609
10. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-1061. http://dx.doi.org/10.1038/leu.2009.38 PMid:19282833
11. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-9. http://dx.doi.org/10.1056/NEJMoa0912614 PMid:20525993
12. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilorinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadlephia chromosome-positive , chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841-851 http://dx.doi.org/10.1016/S1470-2045(11)70201-7
13. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197-203. http://dx.doi.org/10.1038/leu.2012.134 PMid:22699418
14. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-70. http://dx.doi.org/10.1056/NEJMoa1002315 PMid:20525995
15. Kantarjian HM, Shah NP, Cortes JE et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123. http://dx.doi.org/10.1182/blood-2011-08-376087 PMid:22160483
16. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30:3486-3492. http://dx.doi.org/10.1200/JCO.2011.38.7522 PMid:22949154
17. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369(19):1783-96. http://dx.doi.org/10.1056/NEJMoa1306494 PMid:24180494
18. Experts in Chronic Myeloid Leukemia (Kantarjian H. et al). The price of drugs for chronic myeloid leukemia: a reflection on the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121:4439-42 http://dx.doi.org/10.1182/blood-2013-03-490003 PMid:23620577
19. Baccarani M, Efficace F, Rosti G. Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica, 2013, in press.
20. Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared to the general population. Blood 2011;118:4554-4560. http://dx.doi.org/10.1182/blood-2011-04-347575 PMid:21750313
21. O'Brien S, Abboud CN, Akhtari M et al, Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia, Version 1.2013, National Comprehensive Cancer Network (NCCN). J Natl Compr Canc Netw 2012;10:64-110.
22. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus Peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363:2511-2521. http://dx.doi.org/10.1056/NEJMoa1004095 PMid:21175313
23. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-? in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634-1642. http://dx.doi.org/10.1200/JCO.2010.32.0598 PMid:21422420
24. Simonsson B, Gedde-Dahl T, Markevarn B, et al. Combination of pegylated IFN-?2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011;118:3228-3235. http://dx.doi.org/10.1182/blood-2011-02-336685 PMid:21685374
25. Goldman M. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110:2828-2837 http://dx.doi.org/10.1182/blood-2007-04-038943 PMid:17626839
26. Saussele S, Lauseker M, Gratwhol A, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010;115:1880-1885. http://dx.doi.org/10.1182/blood-2009-08-237115 PMid:19965667
27. Warlick E, Ahn KW, Pedersen TL, et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012;119(17):4083-4090. http://dx.doi.org/10.1182/blood-2012-02-409763 PMid:22408257 PMCid:PMC3350369
28. Hehlmann R. How I treat CML blast crisis. Blood 2012;120:737-747 http://dx.doi.org/10.1182/blood-2012-03-380147 PMid:22653972
29. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28-37 http://dx.doi.org/10.1182/blood-2006-01-0092 PMid:16522812 PMCid:PMC1895821
30. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112:3330-8. http://dx.doi.org/10.1182/blood-2008-04-150680 PMid:18684859
31. Müller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23:1957-63. http://dx.doi.org/10.1038/leu.2009.168 PMid:19710700
32. Cross NCP, White HE, Müller MC, et al. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012;26:2172:2175
33. Castagnetti F, Palandri F, Amabile M, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase II trial of the GIMEMA CML WP. Blood 2009; 113:3428-34. http://dx.doi.org/10.1182/blood-2007-08-103499 PMid:19211938
34. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed , previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28:424-30. http://dx.doi.org/10.1200/JCO.2009.25.3724 PMid:20008622
35. Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood. 2009; 114:4933-8. http://dx.doi.org/10.1182/blood-2009-07-232595 PMid:19822896
36. Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010; 28:392-7. http://dx.doi.org/10.1200/JCO.2009.25.4896 PMid:20008621 PMCid:PMC2815701
37. Gurion R, Gafter-Gvili A, Vidal L, et al. Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica 2013;98:95-102. http://dx.doi.org/10.3324/haematol.2012.063172 PMid:22875617 PMCid:PMC3533665
38. Palandri F, Castagnetti F, Soverini S, et al. Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. Haematologica 2009;94:1758-1761. http://dx.doi.org/10.3324/haematol.2009.010496 PMid:19608673 PMCid:PMC2791949
39. Valent P. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Haematologica 2011;96:1395-1397
40. Steegmann JL, Cervantes F, le Coutre P, et al. Off-target effects of BCR-ABL1 inhibitors and their potential long term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 2012;53:2351-2362 http://dx.doi.org/10.3109/10428194.2012.695779 PMid:22616642
41. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013;27:1310-1315. http://dx.doi.org/10.1038/leu.2013.69 PMid:23459450
42. Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013;27:1316-1321. http://dx.doi.org/10.1038/leu.2013.70 PMid:23459449
43. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261-263 http://dx.doi.org/10.1182/blood-2008-09-180604 PMid:19414863
44. Futosi K, Nemeth T, Pick R, et al. Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood 2012;119:4981-4991. http://dx.doi.org/10.1182/blood-2011-07-369041 PMid:22411867 PMCid:PMC3367900
45. Zarbock A. The shady side of dasatinib. Blood 2012;119:4817-4818. http://dx.doi.org/10.1182/blood-2012-03-418582 PMid:22627592
46. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916. http://dx.doi.org/10.1038/nm1446 PMid:16862153
47. Kim TD, le Coutre PD, Schwarz M, et al. Clinical cardiac safety profile of nilotinib. Haematologica 2012;97:883-889 http://dx.doi.org/10.3324/haematol.2011.058776 PMid:22271904 PMCid:PMC3366654
48. Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009;114:2168-2171. http://dx.doi.org/10.1182/blood-2009-01-197186 PMid:19589924
49. Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutations analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118(5):1208-1215. http://dx.doi.org/10.1182/blood-2010-12-326405 PMid:21562040
50. O'Hare T, Shakespeare WX, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-412. http://dx.doi.org/10.1016/j.ccr.2009.09.028 PMid:19878872 PMCid:PMC2804470
51. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory chromosome-positive leukemias. N Engl J Med 2012;367:2075-2088. http://dx.doi.org/10.1056/NEJMoa1205127 PMid:23190221
52. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive of long-term progression-free and overall survival in chronic myeloid leukemia. Leukemia 2012;26:2096-2102. http://dx.doi.org/10.1038/leu.2012.85 PMid:22446502
53. Marin D, Hedgley C, Clark RE, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 2012;120(2):291-294. http://dx.doi.org/10.1182/blood-2012-01-407486 PMid:22645182
54. Neelakantan P, Gerrard G, Lucas C, et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early interventions strategies. Blood 2013;121:2739-2742. http://dx.doi.org/10.1182/blood-2012-11-466037 PMid:23380743
55. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-1035. http://dx.doi.org/10.1016/S1470-2045(10)70233-3
56. Shami PJ, Deininger M. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 2012;26:214-224. http://dx.doi.org/10.1038/leu.2011.217 PMid:21844872
57. TIGER study. http://clinicaltrials.gov/show/NCT01657604
58. Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood 2013;121:5138-44. http://dx.doi.org/10.1182/blood-2013-01-480194 PMid:23678005
59. EUROSKI study. http://www.clinicaltrials.gov/ct2/show/NCT01596114
60. Rosti G, Castagnetti F, Gugliotta G, et al. Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. Cancer Treat Rev 2012;38:241-248. http://dx.doi.org/10.1016/j.ctrv.2011.07.004 PMid:21840128
61. Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011;25:201-210. http://dx.doi.org/10.1038/leu.2010.215 PMid:20861918
62. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-5411. http://dx.doi.org/10.1182/blood-2008-12-196543 PMid:19349618
63. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic response on imatinib. J Clin Oncol 2010;28:2381-2388. http://dx.doi.org/10.1200/JCO.2009.26.3087 PMid:20385986
64. Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013;27:1511-1519. http://dx.doi.org/10.1038/leu.2013.51 PMid:23417029
65. Efficace F, Baccarani M, Breccia M, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 2013. Epub 2013 Sep 13. http://dx.doi.org/10.1007/s11136-013-0523
66. http://groups.eortc.be/qol/
67. Williams LA, Garcia Gonzales AC, Ault P, Mendoza TR, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 2013;122:641-647. http://dx.doi.org/10.1182/blood-2013-01-477687 PMid:23777764
68. http://www3.mdanderson.org/depts/symptomresearch